Click Holdings Limited (NASDAQ:CLIK) Short Interest Down 38.2% in June

Click Holdings Limited (NASDAQ:CLIK) was the recipient of a large decline in short interest in June. As of June 30th, there was short interest totaling 37,691 shares, a decline of 38.2% from the June 15th total of 60,989 shares. Approximately 3.3% of the company’s stock are short sold. Based on an average trading volume of 123,258 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Click stock. Renaissance Technologies LLC acquired a new position in shares of Click Holdings Limited (NASDAQ:CLIK) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned 1.23% of Click at the end of the most recent quarter.

Click Stock Performance

Shares of CLIK stock opened at $1.73 on Friday. Click has a fifty-two week low of $1.32 and a fifty-two week high of $14.40. The stock’s 50-day simple moving average is $1.60 and its 200-day simple moving average is $2.84.

Click (NASDAQ:CLIK) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.10 EPS for the quarter. The company had revenue of $3.79 million during the quarter.

Analysts Set New Price Targets

CLIK has been the subject of a number of analyst reports. Wall Street Zen raised shares of Click to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Click in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Click currently has an average rating of “Sell”.

Click Company Profile

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.